Osimertinib (Tagrisso) is recommended through the Cancer Drugs Fund as a possible treatment for adults with locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small-cell lung cancer. It is only recommended when the disease has got worse after treatment with an EGFR tyrosine kinase inhibitor.
More evidence on osimertinib is being collected, until March 2019. After this NICE will decide whether or not to recommend it for use on the NHS and update the guidance. It will be available through the Cancer Drugs Fund until then.
If you are not eligible for osimertinib but are already taking it, you should be able to continue until you and your doctor decide when best to stop.
Is this treatment right for me?
Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. Read more about making decisions about your care.
Questions to think about
- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?
Information and support
NHS Choices may be a good place to find out more.
These organisations can give you advice and support:
- British Lung Foundation, 0207 688 5555
- Cancer Research UK, 0808 800 4040
- Macmillan Cancer Support, 0808 808 0000
- Roy Castle Lung Cancer Foundation, 0333 323 7200.
You can also get support from your local Healthwatch.
NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.
This page was last updated: 26 October 2016